Phase 3 Trial of Immune System-targeting Treatment for Advanced Multiple Myeloma Begins Dosing
A pivotal Phase 3 clinical trial has begun dosing…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreA pivotal Phase 3 clinical trial has begun dosing…
OncLive, a digital resource platform for oncologists, will welcome 15…
ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can…
A triple regimen composed of Kyprolis (carfilzomib),…
Bluebird bio has officially opened a facility in…
Maintenance therapy with Ninlaro (ixazomib) can prolong…